

RNS Number : 2890D  
Beximco Pharmaceuticals Ltd  
06 September 2024

6 September 2024

## **BEXIMCO PHARMACEUTICALS LIMITED**

### **Update regarding Vice-Chairman, Salman Rahman**

In accordance with AIM Rule 17 and Schedule Two Paragraph (g) of the AIM Rules for Companies, Beximco Pharmaceuticals Limited ("Beximco Pharma", "BPL" or "the Company"; AIM Symbol: BXP, LEI No.: 213800IMBBD6TIOQGB56), discloses that the Central Bank of Bangladesh has dissolved the Board of IFIC Bank, which includes Beximco Pharma Non-Executive Vice-Chairman, Mr Salman Rahman.

For further information please visit [www.beximcopharma.com](http://www.beximcopharma.com) or enquire to:

#### **Beximco Pharma**

S M Rabbur Reza, Chief Operating Officer

Tel: +880 2 58611001, Ext.20111

Mohammad Ali Nawaz, Chief Financial Officer

Tel: +880 2 58611001, Ext.20030

#### **SPARK Advisory Partners Limited (Nominated Adviser)**

Mark Brady / Andrew Emmott / Adam Dawes

Tel: +44 (0) 20 3368 3551 / 3555

#### **SP Angel Corporate Finance LLP (Broker)**

Matthew Johnson

Tel: +44 (0) 20 3470 0470

#### **FTI Consulting**

Simon Conway / Victoria Foster Mitchell / Sam Purewal

Tel: +44 (0) 20 3727 1000

#### **Notes to Editors**

#### **About Beximco Pharmaceuticals Limited**

Beximco Pharma is a leading manufacturer and exporter of medicines based in Bangladesh. Since its inception in 1976, the Company remains committed to health and wellbeing of people across all the continents by providing access to contemporary medicines. Company's broad portfolio of generics encompasses diverse delivery systems such as tablets, capsules, liquids, semi-solids, intravenous fluids, metered dose inhalers, dry powder inhalers, sterile ophthalmic drops, insulins, prefilled syringes, injectables, nebuliser solutions, oral soluble films etc. The Company also undertakes contract manufacturing for multinational and leading global generic pharmaceutical companies.

Beximco Pharma's state-of-the-art manufacturing facilities are certified by global regulatory authorities of USA, Europe, Australia, Canada, GCC and Latin America, among others and it has a geographic footprint in more than 50 countries. More than 5700 employees are driving the company towards achieving its aspiration to be among the most admired companies in the world.

information, please contact [ms@seg.com](mailto:ms@seg.com) or visit [www.ms.com](http://www.ms.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

UPDLFMJTM TBMBTI